Skip to main content
Some text as placeholder. In real life you can have the elements you have chosen. Like, text, images, lists, etc.
What are you looking for?

The Win-Win of End-to-End Outsourcing for Emerging Biotech

On the long road that a compound travels from the lab to the 
pharmacy, sponsors typically engage asset development partners 
in the final stages of product development, but the nature of the relationship between sponsors and partners has been gradually evolving.

Today, sponsors and asset development partners can form an end-to-end, integrated partnership with mutually beneficial objectives. Such a relationship allows for more creative financial structures in which the asset development partner’s incentives are aligned with the sponsor’s own goals.    

Read this article to learn about this new approach, specifically suited for small to mid-sized companies with several assets in early development and a desire to keep a small, fixed-cost footprint.

To download the free whitepaper, fill out the form below:

Interested in Syneos Health?